Clinical Trial Update: A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Trial update for HS-10296 in non-small cell lung cancer across Phase 1 and Phase 2 evaluating safety, PK, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HS-10296 (HS-10296)

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Nonsmall Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN | Results posted: 2023-01-23